Key facts
- It has raised $40.6M; the latest was Early Stage VC ($40.6M) in Apr 2026.
- Notable investors include Oost NL, Athos (Family Office), MIG AG, Meneldor.
- Status: Privately Held (backing).
- ·The complete investor list — 4 names
- ·Watchlist + deal alerts for TIBEAY Biosciences
- ·The full record, as it builds
Funding rounds
No funding rounds for TIBEAY Biosciences are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About TIBEAY Biosciences
Operator of a clinical biotechnology company intended to develop therapies for acute neurological conditions. The company offers a substance that reduces secondary brain damage in severe traumatic brain injury, enabling patients to improve their neurological condition and overall quality of life.
- Sector
- Healthcare
- HQ
- Druten, Netherlands
- Founded
- 2025
- Employees
- 4
- Website
- tibeay-biosciences.com/
- Ownership
- Privately Held (backing)
TIBEAY Biosciences doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in TIBEAY Biosciences shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on TIBEAY Biosciences in its N-PORT filings yet. We sweep new filings monthly.